

Supporting Information

Okazaki et al. 10.1073/pnas.1104423108

SI Materials and Methods

Expression Vectors and Cell Lines. Mouse activation-induced cytidine deaminase (mAID) cDNA was cloned in-frame to the 5' end of EGFP-FLAG-HA sequence in pBluescript by a three-fragment ligation, and the resulting cDNA cassette encoding mAID-EGFP-FLAG-HA (mAID-GF) was excised and cloned into a retroviral vector pFB-ires-Puro (pFBP). Expression vectors of human AID (hAID) and AID mutants of human and mouse origins were generated by replacing the mAID fragment in pFBP-mAID-GF with the corresponding AID cDNAs. Retroviruses were produced by transient transfection of each pFBP vector into Plat-E cells using FuGENE 6 transfection reagent (Roche) and used to infect CH12F3-2 cells. Infected cells were selected with puromycin.

Immunopurification and Mass Spectrometry. Cytosolic extracts were prepared as described (1). Briefly, cells were washed once and resuspended in 1 mL/10⁸ cells of hypotonic buffer [10 mM Hepes (pH 7.9), 1.5 mM MgCl₂, 10 mM NaCl, Complete Protease Inhibitor Mixture (Roche)] and incubated on ice for 30 min. Cells were then disrupted by Dounce homogenization (50 strokes with a tight pestle) and centrifuged at 800 × g for 15 min at 4 °C. Supernatants were mixed with 0.11 volume of 10× cytosolic extraction buffer [0.3 M Hepes (pH 7.9), 30 mM MgCl₂, and 1.4 M NaCl] and ultracentrifuged at 100,000 × g for 1 h at 4 °C. Resulting supernatants were supplemented with 10% glycerol and used as cytosolic extracts. Cytosolic extracts were precleared with mouse IgG-agarose (Sigma) for 30 min at 4 °C, then incubated with anti-FLAG M2-agarose (Sigma) for 2 h at 4 °C. After extensive washing with immunoprecipitation (IP) buffer [20 mM Hepes (pH 7.9), 1.5 mM MgCl₂, 150 mM NaCl, 0.2 mM EDTA, 10% glycerol, Complete Protease Inhibitor Mixture (Roche)], coimmunoprecipitated proteins were eluted twice with 100 μg/mL

of 3× FLAG peptides in IP buffer. The eluates were separated on 6–9% SDS/PAGE gels and visualized with MS-compatible silver staining. Each band on gels was excised with a scalpel and subjected to MS as described previously (2). Briefly, proteins were in-gel digested with trypsin, and molecular-mass analysis of tryptic peptides was performed by MALDI-TOF/MS with an Ultraflex MALDI-TOF/TOF system (Bruker Daltonics). Mass spectra were subjected to peptide mass fingerprinting using the Mascot (Matrix Science) search engine against the NCBI database.

IP and Western Blotting. IP with anti-FLAG antibody was performed as described above, except that coimmunoprecipitated proteins were eluted by boiling in Laemmli buffer. For IP with anti-Spt6 antibody, cytosolic extracts were first precleared with Protein G-Sepharose pretreated with 0.1% BSA in IP buffer for 30 min at 4 °C, then incubated with anti-Spt6 mAb 2-1 (kindly provided by Dr. Handa, Tokyo Institute of Technology, Tokyo, Japan) for 1 h at 4 °C, and the immune complexes were captured for 1 h at 4 °C by Protein G-Sepharose pretreated as above. Coimmunoprecipitated proteins were eluted by boiling in Laemmli buffer. Eluted proteins were separated by SDS/PAGE, transferred to PVDF membranes, and probed with the following antibodies: an anti-Spt6 polyclonal antibody S2-B generated in our laboratory, anti-FLAG M2 antibody (Sigma), anti-Nucleolin polyclonal antibody (Novus Biologicals), anti-eEF1α monoclonal antibody (Upstate), and anti-KAP1 polyclonal antibody (Abcam). Signal was visualized using ECL Plus Western Blotting Detection Reagents (GE Healthcare) and detected with LAS4000 (Fujifilm). To analyze the effect of DNase I and RNase A treatment, cytosolic extracts were incubated at room temperature for 10 min either with RNase A (130 μg/mL) or with DNase I (4,000 U/mL) and subjected to IP.

1. Dignam JD, et al. (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. *Nucleic Acids Res* 11:1475–1489.

2. Takamatsu H, et al. (2009) Anti-moesin antibodies in the serum of patients with aplastic anemia stimulate peripheral blood mononuclear cells to secrete TNF-alpha and IFN-gamma. *J Immunol* 182:703–710.

Table S1. Mutants of AID used in this study

AID mutants	CSR activity	SHM activity	Binding with Spt6	Reference
WT	100	100	+	
P20 (34-aa insertion at residue 182)	3	71	+	1
P13 (M139V)	5	<1	–	1
P7 (R24W)	1	<1	+	1
M6A	4	1	–	
N7A	90	47	+	
R8A	107	139	+	
R9A	89	93	+	
K10A	59	38	+	
K10R	80	54	+	
L172A	65	28	+	2
JP8Bdel	14	548	ND	2, 3
mG23S	97	11	+	4
W20K	103	17	+	4
W20K-ΔC	–	±	+	
V18S-R19V	53	5	+	4
V18S-R19V-ΔC	–	–	+	
Δ2-26	–	–	–	
Δ2-26-ΔC	–	–	–	
Δ2-5	+	+	+	
Δ2-10	0	0	–	3, 4
Δ2-10-ΔC	–	–	–	

All constructs except for mG23S are derived from human AID. Expected activities for CSR and SHM are indicated as +, –, or ±. CSR, class switch recombination; ΔC, deletion of residues 183–198, ND, not done.

1. Ta VT, et al. (2003) AID mutant analyses indicate requirement for class-switch-specific cofactors. *Nat Immunol* 4:843–848.
2. Doi T, et al. (2009) The C-terminal region of activation-induced cytidine deaminase is responsible for a recombination function other than DNA cleavage in class switch recombination. *Proc Natl Acad Sci USA* 106:2758–2763.
3. Ito S, et al. (2004) Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1. *Proc Natl Acad Sci USA* 101:1975–1980.
4. Shinkura R, et al. (2004) Separate domains of AID are required for somatic hypermutation and class-switch recombination. *Nat Immunol* 5:707–712.

Table S2. Proteins interacting with AID in 293T

Symbol	Description	CSR by knockdown*	Knockdown efficiency*
A.	Protein with known direct or indirect interaction with DNA or RNA		
DDX17	DEAD (Asp-Glu-Ala-Asp) box polypeptide 17	0.79 ± 0.034	0.32 ± 0.025
DDX20	DEAD (Asp-Glu-Ala-Asp) box polypeptide 20	1.0 ± 0.046	0.12 ± 0.011
hnRNPA1	heterogeneous nuclear ribonucleoprotein A1	ND	ND
IGF2BP1	insulin-like growth factor 2 mRNA binding protein 1	0.93 ± 0.05	0.36 ± 0.13
PABPC1	poly(A) binding protein, cytoplasmic 1	1.4 ± 0.02	0.46 ± 0.14
B.	Proteins involved in degradation of proteins		
PSME3	proteasome (prosome, macropain) activator subunit 3	1.1 ± 0.034	0.55 ± 0.084
C.	Proteins involved in cell cycle regulation		
AFF4	AF4/FMR2 family, member 4	0.94 ± 0.034	0.51 ± 0.27

CSR, class switch recombination; ND, not done.

*Ratio to the control siRNA.

Table S3. Mutation frequency in the GFP sequence in siRNA-treated BL2 cells expressing JP8Bdel-ER

Oligo	Clone (mutated/total)	Mutated (deletion or insertion)	Total bases	Mutation frequency ($\times 10^{-4}$)
OHT+				
AID-1 (M)	5/24	6 (0)	39,792	1.5
AID-2 (M)	0/24	0 (0)	39,792	<0.3
AID-3 (M)	1/24	1 (0)	39,792	0.3
SPT6-1 (L)	17/25	34 (0)	41,450	8.2
SPT6-2 (L)	15/24	26 (1)	39,792	6.5
SPT6-3 (M)	17/24	24 (0)	39,792	6.0
Ctrl-L	12/24	18 (0)	39,792	4.5
Ctrl-M	14/25	21 (0)	41,450	5.1
OHT-				
AID-1 (M)	2/24	2 (0)	39,792	0.5
AID-2 (M)	2/24	2 (0)	39,792	0.5
AID-3 (M)	0/24	0 (0)	39,792	<0.3
SPT6-1 (L)	3/24	3 (0)	39,792	0.8
SPT6-2 (L)	1/24	1 (0)	39,792	0.3
SPT6-3 (M)	0/24	0 (0)	39,792	<0.3
Ctrl-L	0/24	0 (0)	39,792	<0.3
Ctrl-M	0/24	0 (0)	39,792	<0.3

The control siRNA oligo corresponding to each test siRNA is indicated as L (Ctrl-L) or M (Ctrl-M).

Table S4. Mutation frequency in the GFP sequence in NIH 3T3 cells expressing mutant hAID-GFs

hAID-GF constructs	Clone (mutated/total)	Mutated (deletion or insertion)	Total bases	Mutation frequency ($\times 10^{-4}$)
WT	26/43	75 (1)	41,495	18.1
M6A	1/45	1 (0)	43,425	0.2
N7A	20/46	38 (1)	44,390	8.6
R8A	25/35	85 (5)	33,775	25.2
R9A	25/45	73 (2)	43,425	16.8
K10A	18/47	31 (2)	45,355	6.8
K10R	21/46	43 (5)	44,390	9.7
Mock	3/46	3 (0)	44,390	0.7